SCHEMBL96129

SCHEMBL96129

CC(=O)c1ccc(O)cc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B1 P14061 4/20 0.56
ALDH1A1 P00352 2/20 0.47
CYP3A4 P08684 1/20 0.47
HPGD P15428 1/20 0.47
MAPK1 P28482 1/20 0.47
CES2 O00748 1/20 0.46
CA12 O43570 4/20 0.45
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
CA7 P43166 4/20 0.45
CA9 Q16790 4/20 0.45
CA14 Q9ULX7 4/20 0.45
TSHR P16473 1/20 0.45
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
S1PR4 O95977 1/20 0.44
GLA P06280 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
MIF P14174 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29384682 1.00 HSD17B1 (0.56) HSD17B1ALDH1A1CYP3A4HPGDMAPK1
SCHEMBL10370024 0.84 CES2 (0.60) HSD17B1ALDH1A1CYP3A4CES2CA12
SCHEMBL764844 0.84 SMN1; SMN2 (0.50) HSD17B1ALDH1A1CYP3A4HPGDCES2
SCHEMBL39526 0.82 CA12 (0.61) HSD17B1ALDH1A1CYP3A4HPGDCES2
SCHEMBL9216747 0.82 HSD17B1 (0.47) HSD17B1ALDH1A1CYP3A4HPGDMAPK1
SCHEMBL16520525 0.81 ALDH1A1 (0.55) HSD17B1ALDH1A1CYP3A4HPGDMAPK1
SCHEMBL14900218 0.80 HSD17B1 (0.46) HSD17B1ALDH1A1CYP3A4HPGDCES2
SCHEMBL27500611 0.80 CA12 (0.59) HSD17B1ALDH1A1CYP3A4HPGDCES2
SCHEMBL5952602 0.80 MKNK1 (0.47) HSD17B1ALDH1A1CES2CA12CA1
SCHEMBL27659033 0.80 CA12 (0.59) HSD17B1ALDH1A1CYP3A4HPGDCES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 482 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114146071-B Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome 西北农林科技大学深圳研究院 2023-02-28 CN claimed
CN-114146071-A Application of paeonol and its derivatives in preventing and treating leukoplakia syndrome 西北农林科技大学深圳研究院 2022-03-08 CN claimed
US-6461417-B1 Ink compositions XEROX CORPORATION 2002-10-08 US claimed
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS RIZUN NODARI (US) 2026-02-05 US disclosed
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE YUZU LV LLC (US) 2026-01-29 US disclosed
US-20250360486-A1 Biorefining Method LICELLA PTY LTD (AU) 2025-11-27 US disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 US disclosed
US-12458653-B2 Cannabis based therapeutic and method of use YUZU LV LLC (US) 2025-11-04 US disclosed
US-12427176-B2 Enriched mineral pitch resin products and methods of manufacturing enriched mineral pitch resin products RIZUN NODARI (US) 2025-09-30 US disclosed
US-12421193-B2 GPR52 modulators and methods of use NEUROCRINE BIOSCIENCES, INC. (US) 2025-09-23 US disclosed
US-12409437-B2 Biorefining method LICELLA PTY LTD (AU) 2025-09-09 US disclosed
EP-0161105-A2 Record material APPLETON PAPERS INC. (US) 1985-11-13 EP disclosed
US-4535347-A HYDROXYANILIDES, PHENOLIC DEVELOPERS, CHROMOGENIC COMPOUNDS; BLOOMRESISTANCE APPLETON PAPERS INC. (US) 1985-08-13 US disclosed
US-4514416-A Amidine compound, process for producing same and anti-complement agent comprising same TORII & CO. LTD. (JP) 1985-04-30 US disclosed
US-RE31715-E ESTERS OF 2-METHYLBUTYLPHENOL THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 1984-10-30 US disclosed
US-4470057-A CHROMOGENIC COMPOUND, ACIDIC DEVELOPERS, AND PHENYLHYDROXYNAPHTHOATE APPLETON PAPERS INC. (US) 1984-09-04 US disclosed
EP-0100196-A2 Thermally responsive record material APPLETON PAPERS INC. (US) 1984-02-08 EP disclosed
US-4394496-A POLYEPOXEDES WITH GOOD HIGH TEMPERATURE PROPERTIES THE DOW CHEMICAL COMPANY (US) 1983-07-19 US disclosed
US-4195916-A ELECTROOPTIC DISPLAY DEVICES, OPTICAL PHENOLIC ESTERS THE SECRETARY OF STATE FOR DEFENCE IN HER BRITANNIC MAJESTY'S GOVERNMENT OF THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND (GB) 1980-04-01 US disclosed
US-4029594-A Novel liquid crystal compounds and electro-optic devices incorporating them RCA CORPORATION (US) 1977-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260027136-A1 CANNABIS BASED THERAPEUTIC AND METHOD OF USE CNR1, CNR2, OPRM1 HSD17B1 318/4885ALDH1A1 1420/4885CYP3A4 1136/4885
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK HSD17B1 2709/4885ALDH1A1 4075/4885CYP3A4 4471/4885
US-20260034186-A1 ENRICHED MINERAL PITCH RESIN PRODUCTS AND METHODS OF MANUFACTURING ENRICHED MINERAL PITCH RESIN PRODUCTS TRPV1, SOST, RUNX1 HSD17B1 1461/4885ALDH1A1 4768/4885CYP3A4 1979/4885
US-12421193-B2 GPR52 modulators and methods of use GPR52, GPR68, GPR35 HSD17B1 1245/4885ALDH1A1 1831/4885CYP3A4 2659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.